THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 83 filers reported holding THERAVANCE BIOPHARMA INC in Q4 2015. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $128,951 | -49.0% | 14,942 | -38.8% | 0.00% | – |
Q2 2023 | $252,623 | +72.7% | 24,408 | +81.1% | 0.00% | – |
Q1 2023 | $146,257 | +1174.2% | 13,480 | +1217.7% | 0.00% | – |
Q4 2022 | $11,478 | -45.3% | 1,023 | -49.4% | 0.00% | – |
Q3 2022 | $21,000 | -12.5% | 2,022 | -22.4% | 0.00% | – |
Q2 2022 | $24,000 | -66.2% | 2,607 | -65.0% | 0.00% | – |
Q1 2022 | $71,000 | -78.7% | 7,442 | -75.3% | 0.00% | – |
Q4 2021 | $334,000 | +193.0% | 30,104 | +94.7% | 0.00% | – |
Q3 2021 | $114,000 | -95.9% | 15,459 | -91.8% | 0.00% | -100.0% |
Q2 2021 | $2,750,000 | -26.3% | 189,345 | +3.5% | 0.00% | 0.0% |
Q1 2021 | $3,733,000 | -22.8% | 182,865 | -32.8% | 0.00% | 0.0% |
Q4 2020 | $4,836,000 | +18.2% | 272,162 | -1.7% | 0.00% | 0.0% |
Q3 2020 | $4,092,000 | -30.7% | 276,786 | -1.5% | 0.00% | -50.0% |
Q2 2020 | $5,901,000 | +27.7% | 281,099 | +40.6% | 0.00% | 0.0% |
Q1 2020 | $4,620,000 | -9.3% | 199,909 | +1.7% | 0.00% | +100.0% |
Q4 2019 | $5,091,000 | +68.9% | 196,617 | +27.1% | 0.00% | 0.0% |
Q3 2019 | $3,014,000 | +25.7% | 154,744 | +5.4% | 0.00% | 0.0% |
Q2 2019 | $2,397,000 | -29.7% | 146,763 | -2.4% | 0.00% | 0.0% |
Q1 2019 | $3,408,000 | +1.3% | 150,321 | +14.3% | 0.00% | 0.0% |
Q4 2018 | $3,363,000 | -20.1% | 131,462 | +2.1% | 0.00% | 0.0% |
Q3 2018 | $4,209,000 | +44.7% | 128,820 | +0.4% | 0.00% | 0.0% |
Q2 2018 | $2,909,000 | -12.2% | 128,257 | -6.1% | 0.00% | 0.0% |
Q1 2018 | $3,312,000 | -12.3% | 136,562 | +0.8% | 0.00% | 0.0% |
Q4 2017 | $3,777,000 | -5.8% | 135,414 | +15.7% | 0.00% | 0.0% |
Q3 2017 | $4,009,000 | +13.5% | 117,079 | +32.0% | 0.00% | 0.0% |
Q2 2017 | $3,533,000 | +197.4% | 88,688 | +174.8% | 0.00% | – |
Q1 2017 | $1,188,000 | +27.7% | 32,270 | +10.6% | 0.00% | – |
Q4 2016 | $930,000 | +100.0% | 29,170 | +127.3% | 0.00% | – |
Q3 2016 | $465,000 | +66.1% | 12,833 | +4.1% | 0.00% | – |
Q2 2016 | $280,000 | +62.8% | 12,331 | +35.0% | 0.00% | – |
Q1 2016 | $172,000 | +19.4% | 9,132 | +3.9% | 0.00% | – |
Q4 2015 | $144,000 | +82.3% | 8,789 | +22.4% | 0.00% | – |
Q3 2015 | $79,000 | -52.4% | 7,181 | -43.7% | 0.00% | – |
Q2 2015 | $166,000 | -34.6% | 12,754 | -12.9% | 0.00% | – |
Q1 2015 | $254,000 | +161.9% | 14,640 | +122.8% | 0.00% | – |
Q4 2014 | $97,000 | -53.1% | 6,571 | -26.9% | 0.00% | – |
Q3 2014 | $207,000 | -35.7% | 8,986 | -11.2% | 0.00% | – |
Q2 2014 | $322,000 | – | 10,114 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Link Fund Solutions Ltd | 5,251,349 | $135,459,000 | 69.86% |
Chescapmanager LLC | 949,006 | $24,570,000 | 3.61% |
Baupost Group | 9,309,168 | $241,014,000 | 2.66% |
Rock Springs Capital Management LP | 655,200 | $16,963,000 | 0.54% |
Rubric Capital Management LP | 173,400 | $4,489,000 | 0.51% |
Newtyn Management, LLC | 173,300 | $4,487,000 | 0.41% |
NJ State Employees Deferred Compensation Plan | 38,142 | $988,000 | 0.17% |
King Wealth Management Group | 22,500 | $583,000 | 0.15% |
Virtus ETF Advisers LLC | 29,216 | $756,000 | 0.12% |
JACOBS LEVY EQUITY MANAGEMENT, INC | 452,615 | $11,718,000 | 0.12% |